Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Spinal Anesthesia Using Lidocaine and Sufentanil and (Transient Neurological Symptoms) TNS

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2011 by Vestre VikenHF Kongsberg Sykehus.
Recruitment status was  Recruiting
Information provided by:
Vestre VikenHF Kongsberg Sykehus Identifier:
First received: January 21, 2011
Last updated: May 26, 2011
Last verified: January 2011

The purpose of this study is to find out whether patients receiving spinal anesthesia containing lidocaine and sufentanil get transient neurological symptoms.

Transient Neurological Symptoms

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Spinal Anesthesia Using Lidocaine and Sufentanil and TNS (=Transient Neurological Symptoms)

Resource links provided by NLM:

Further study details as provided by Vestre VikenHF Kongsberg Sykehus:

Estimated Enrollment: 200
Study Start Date: January 2011

Ages Eligible for Study:   19 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Patients who are submitted for surgery at a local hospital and where spinal anesthesia is indicated.


Inclusion Criteria:

  • adults over the age of eighteen years

Exclusion Criteria:

  • patient refuse spinal anesthesia
  • spinal anesthesia is contraindicated
  • pregnancy
  • patient is incapable of giving consent
  • diabetes
  • neurological disorders
  • chronic pain
  • chronic use of analgesics
  • spinal anesthesia within five days before the actual surgery
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01283087

Contact: Britt-Marie Berling, MD, PhD +4732116000

Ringerike Sykehus Recruiting
Hønefoss, Norway, No 3501
Contact: Britt-Marie Berling, MD, PhD    +4732116000   
Vestre Viken HF Ringerike Sykehus Recruiting
Hønefoss, Norway, NO-3510
Contact: Britt-Marie Berling, MD, PhD    +4732116000   
Principal Investigator: Britt-Marie Berling, MD, PhD         
Sponsors and Collaborators
Vestre VikenHF Kongsberg Sykehus
Study Chair: halfdan Aas, MD, PhD Vestre Viken HF
Study Chair: halfdan Aas, MD, PhD VestreViken HF
  More Information

No publications provided

Responsible Party: Halfdan Aas, Vestre Viken HF Identifier: NCT01283087     History of Changes
Other Study ID Numbers: 400229
Study First Received: January 21, 2011
Last Updated: May 26, 2011
Health Authority: Norway: Directorate of Health

Keywords provided by Vestre VikenHF Kongsberg Sykehus:
Spinal anesthesia

Additional relevant MeSH terms:
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Anesthetics, Local
Anti-Arrhythmia Agents
Cardiovascular Agents
Central Nervous System Agents
Central Nervous System Depressants
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Sodium Channel Blockers
Therapeutic Uses
Voltage-Gated Sodium Channel Blockers processed this record on November 24, 2014